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Tackling the MDR-TB epidemic in Ukraine: every little
helps … and much more needed
Dear Editor,
The 2016 TBnet Academy, a meeting to support collabor-
ation and learning about tuberculosis (TB) amongst stu-
dents, doctors and researchers from across Europe, was
held in Odessa, Ukraine. We witnessed first-hand the com-
mitment of local healthcare professionals to tackle the
increasing multi-drug-resistant TB (MDR-TB) burden.
Ukraine is one of the WHO’s 30 high-burden countries for
MDR-TB.1 In 2014, 8000 patients started on MDR-TB
treatment, accounting for 22% of all new TB cases.1
We write this letter to share the progress being made
locally, to highlight the difficulties being faced, and to call
for ever stronger international collaboration to tackle the
MDR-TB epidemic.
Access to key laboratory diagnostics has improved signifi-
cantly within Ukraine. Since 2011 rapid liquid culture
(BACTEC MGIT, Becton Dickinson, USA) and molecular
tools (GeneXpert, Cepheid, USA), procured by the Global
Fund, are being systematically introduced across the country.
Ukraine has developed a national electronic TB register and
international funding has improved the coverage of anti-
retroviral therapy (ART) for HIV/TB co-infected patients.
Local initiatives have led to the allocation of regional funds for
the renovation of TB facilities and have also developed new
international collaborations (http://cordis.europa.eu/project/
rcn/108387_en.html).
Unfortunately, the impact of the military conflict and the
resultant economic downturn puts the progress in TB con-
trol at significant risk.2 Due to rising inflation salaries for
healthcare workers (HCWs) have effectively fallen by a third
making the retention of HCWs skilled in TB ever more chal-
lenging (http://data.worldbank.org/indicator/FP.CPI.
TOTL.ZG?locations=UA). We also observed shortages of
drugs (rifampicin), basic infection control equipment for
staff and limited access to HIV testing for TB patients.
Many are only provided with one of the two tests required
to be offered ARTs, thus denying access to live-saving treat-
ment. Hospital facilities are still limited and overcrowded
while the management of MDR/extensively drug-resistant
(XDR)-TB patients in communal rooms is a major risk for
nosocomial transmission.3 Newly approved MDR-TB drugs,
such as Bedaquiline and Delamanid, are not yet available in
Ukraine, despite the country participating in clinical trials to
prove the efficacy of Bedaquiline. This lack of access to new
and existing reserve drugs contributes to poor cure rates
amongst MDR/XDR-TB patients.4
The End TB strategy identifies the need for ‘political
commitment’ to ‘support global TB… control’.5 With
increasing political isolationism across Europe and beyond,
one thing is clear: to tackle the rise of MDR-TB better inter-
national collaboration is essential.
Ukraine illustrates the benefits that international collabor-
ation and support can bring to TB control within a country,
but is a stark reminder of the threat to global health posed by
MDR-TB. As a group of students and doctors, and research-
ers from across Europe, we call for increased international
funding, collaboration and expertise exchange to ensure that
we succeed in the fight against TB and MDR-TB.
Submitted on behalf of the Attendees of the 2016 TBnet
Academy (a full list of attendees is available as supplementary
data).
Supplementary data
Supplementary data are available at the Journal of Public
Health online.
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